TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: neuropsychology change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: pain scale change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory markers change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Burnout rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical and Biological Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ridge widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ridge heights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of correct/incorrect car booster safety seat, seat belt, and bicycle helmet placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by Quick DASH
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Dupilumab Concentration in Serum (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clock Genes expression in peripheral blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capillary Blood Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to computer-assisted surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incremental Area Under the Plasma Triglyceride Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Skin Tightening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Biological markers of mesenteric ischemia (IFABP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Health assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum Anti-HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With First Biopsy Proven Acute Rejection (BPAR) at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glomerular Filtration Rate (GFR) by Nankivell Equation at Month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Performance on Information Integration Learning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance on Weather Prediction Learning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Performance on N-Back Working Memory Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Visual Evoked Potential Amplitude using Electroencephalograph (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Richmond Agitation Sedation Score (RASS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Lactulose in bowel preparation quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Acute Serious Bacterial Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicity (DTL)
Endpoint domain: Adverse events/effects
Primary endpoint: Postpartum weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immunogenicity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MTD of radiation delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue localization of 111In-BC8-DOTA Ab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Times of spontaneous vocal cords activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Times of movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Graft Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximal exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC 0-24h) of alcohol concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ANI Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function measurement (MFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Early Clinical Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Late Clinical Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anticoagulant Discontinuation Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: proportion of subjects with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of subjects who develop >150 mIU/ml measles IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in the WOMAC Composite Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of PD1 and PD1 ligand postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tolerated dose (MTD) of clofarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity profile associated with clofarabine
Endpoint domain: Adverse events/effects
Primary endpoint: overall response rate, plus partial response of clofarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solicited local and systemic reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited adverse events of all severities
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of serious adverse events and suspected unexpected serious adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Time-Matched Mean Difference in Corrected QT Interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of the algorithm
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinic immunologic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinic histopathologic features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methamphetamine Withdrawal Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in blood pressure values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in HBA1C values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in lipid values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inspiratory Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cortical Excitability change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ESAT questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FHbF (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbF (g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of cTOI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saccharine transit time test (STT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Vanucizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Objective Response According to RECIST 1.1 Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Early prevention of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of students that took a serving of fruit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of students that took a serving of vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of students that took an entree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in log10 HCV RNA Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in mRNA levels of Visfatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Relapse Free Subjects
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence rate of lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area Under the Curve of Plasma Naproxen From 0 to t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The time of commencement of regular oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nail aesthetical results
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: local response of laser ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: size of the treated lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid input to output ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of remission of ulcerative colitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: haemodynamic collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in YGTSS Total Tic Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal biological dose (OBD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural respiratory drive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Unplanned cardiovascular hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variation rate of SUV(BSA max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective appetite ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Treshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Perinatal Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean wall thickness of paired grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tolerance for the patient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neuropsychological testing score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daytime and night-time pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Androgenetic Alopecia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coping with Toddlers' Negative Emotion Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acne lesions counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acne severity grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of GSK1325756
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes towards end of life issues
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: RatioCmax (serum glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RatioAUC(0-4) (serum glucose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax (plasma metformin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC (0-tlast) (plasma metformin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC (plasma metformin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brief Psychiatric Rating Scale (BPRS) at 60 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Montgomery Asberg Depression Rating Scale (MADRS) at 60 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical Global Impression (CGI) at 60 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global Assessment of Functioning (GAF) at 60 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sheehan Disability Scale (SDS) at 60 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Area under the ethinylestradiol plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the levonorgestrel plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: overall quality of bowel cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Positive Blood Cultures (PBCs)
Endpoint domain: Adverse events/effects
Primary endpoint: Residual neuromuscular block incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Step Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Weeks Participants Adhered to Step Count Recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee Society knee score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent of Caregivers Reporting Designated Care Coordinator
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Number of subjects with cleared VRE colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preliminary tolerability profile
Endpoint domain: Adverse events/effects
Primary endpoint: Grading of spoke-wheel sign
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response to influenza vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Nintedanib
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of MACE at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of cooled patients who reach ≤34° at PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enrollment to the yoga therapy protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to the yoga therapy protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion in the yoga therapy protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients with any adverse experience
Endpoint domain: Adverse events/effects
Primary endpoint: Proportions of patients with HIV-1 RNA levels of less than 50 milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of patients with HIV-1 RNA levels of less than 400 copies per milliliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in CD4 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 1 AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCtau Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day 1 Plasma Cmax Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax Values on Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Selective Reminding Test - Total Immediate Recall (SRT-IR)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to the first incident ischemic stroke event
Endpoint domain: Mortality/survival
Primary endpoint: Time to the first recurrent intracerebral haemorrhage event
Endpoint domain: Mortality/survival
Primary endpoint: change in balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily diarrhea frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quantitative Myasthenia Gravis score (QMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Function Test (VC in liters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Manual Muscle Test (MMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes of percentage of lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes of Erythrocyte sedimentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Ferritin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes of C-Reactive Protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of combined Appraisal and Help-seeking intervals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of Diagnostic interval
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of Pre-Treatment interval
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients treated with limited stage cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of curative-intent treatment
Endpoint domain: Mortality/survival
Primary endpoint: Area under the plasma concentration versus time curve (AUClast) of venglustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-being Subscale of the Mental Health Inventory (MHI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: z-BMI in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrode Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrode thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rustogi Modification of the Navy Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse-free Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day Urinary Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Nocturia Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of patients with clinical significant findings in ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Permanent discontinuation of study medication
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in 2 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in WOMAC Pain Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival without disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Physical Functioning Inventory (PFI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in Brachial Skin Laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: confirmed Expanded Disability Status Scale (EDSS) deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of ambulation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first relapse requiring corticoid treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Tryptase Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes